Tamoxifen: From breast cancer therapy to the design of a postmenopausal prevention maintenance therapy

Clinical Oncology

Volumn 9, Issue 6, 1997, Pages 390-394

  Jordan, V C ^a   MacGregor, J I ^a   Tonetti, D A ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIESTROGEN; CONJUGATED ESTROGEN; DROLOXIFENE; ESTROGEN; ESTROGEN RECEPTOR; RALOXIFENE; TAMOXIFEN;

ARTICLE; BREAST CANCER; CANCER PREVENTION; CLINICAL RESEARCH; DRUG DESIGN; DRUG TARGETING; ENDOMETRIUM CANCER; FEMALE; HIGH RISK POPULATION; HUMAN; MAINTENANCE THERAPY; POSTMENOPAUSE; PRIORITY JOURNAL; PROPHYLAXIS; RECEPTOR BINDING; STRUCTURE ACTIVITY RELATION;

EID: 0031472657     PISSN: 09366555     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0936-6555(97)80134-3     Document Type: Article

References (36)

1. Grodstein F, Stampfer M. The epidemiology of coronary heart disease and estrogen replacement in postmenopausal women. Prog Cardiovasc Dis 1995;38:199-210
2. Lindsay R, Tohme JF. Oestrogen treatment of patients with established postmenopausal osteoporosis. Obstet Gynecol 1990; 76:290-5.
3. Tang M-X, Jacobs D, Stern Y, et al. Effect of oestrogen during menopause on risk and age at onset of Alzheimer's disease. Lancet 1996;348:429-432.
4. Sherwin BB. Hormones, mood, and cognitive functioning in postmenopausal women. Obstet Gynecol 1996;87:S20-6.
5. Cohen CJ, Rahaman J. Endometrial cancer: management of high risk and recurrence including the tamoxifen controversy. Cancer 1995;76:2044-52.
6. Steinberg KK, Thacker SB, Smith SJ, et al. A meta-analysis of the effect of estrogen replacement therapy on the risk of breast cancer. JAMA 1991;265:1985-90.
7. Early Breast Cancer Trialists' Collaborative Group. Systemic treatment of early breast cancer by hormonal, cytotoxic or immune therapy. Lancet 1992;339:1-15, 71-85.
8. Love RR, Wiebe DA, Newcomb PA, et al. Effects of tamoxifen on cardivascular risk factors in postmenopausal women. Ann Intern Med 1991;115:860-4.
9. McDonald CC, Stewart JH, for the Scottish Breast Cancer Committee. Fatal myocardial infarctions in the Scottish adjuvant tamoxifen trial. BMJ 1991;303:435-7.
10. Love RR, Mazess RB, Barden HS, Epstein S, et al. Effects of tamoxifen on bone mineral density in postmenopausal women with breast cancer. N Engl J Med 1992;326:852-6.
11. Assikis VJ, Neven P, Jordan VC, Vergote T. A realistic clinical perspective of tamoxifen and endometrial carcinogenesis. Eur J Cancer 1996;32A:1464-6.
12. Jordan VC. A current view of tamoxifen for the treatment and prevention of breast cancer. Br J Pharmacol 1993;110:507-17.
13. Powles TJ, Hardy JR, Ashley SE, Farrington GM, et al. A pilot trial to evaluate the acute toxicity and feasibility of tamoxifen for prevention of breast cancer. Br J Cancer 1989;60:126-33.
14. Powles TJ, Tillyer CP, Jones AL, et al. Prevention of breast cancer with tamoxifen: an update on the Royal Marsden pilot program. Eur J Cancer 1990;26:680-4.
15. Powles TJ, Jones AL, Ashley SE, et al. The Royal Marsden Hospital pilot tamoxifen chemoprevention trial. Breast Cancer Res Treat 1994;31:73-82.
16. Powles TJ, Hickish T, Kanis JA, Tidy A, Ashley S. Effect of tamoxifen on bone mineral density measured by dual-energy X-ray absorptiometry in healthy premenopausal and postmenopausal women. J Clin Oncol 1996;14:78-84.
17. Jordan VC, Morrow M. An appraisal of strategies to reduce the incidence of breast cancer. Stem Cells 1993;11:252-62.
18. Lerner LJ, Jordan VC. Development of antiestrogens and their use in breast cancer (Eighth Cain Memorial award lecture). Cancer Res 1990;50:4177-89.
19. Jordan VC. Alternate antiestrogens and approaches to the prevention of breast cancer. J Cell Biochem Suppl 1995;22:51-7.
20. Tonetti DA, Jordan VC. Targeted antiestrogens to treat and prevent diseases in women. Mol Med Today 1996;2:218-23.
21. Tonetti DA, Jordan VC. Design of an ideal hormone replacement therapy for women. Mol Carcinog 1996;17:108-111.
22. Kuiper GGJM, Enmark E, Pelto-Huikko M, Nilsson S, Gustafsson J-A. Cloning of a novel estrogen receptor expressed in rat prostate and ovary. Proc Natl Acad Sci USA 1996;93:5925-30.
23. Baniahamad C, Nawaz Z, Banaihmad A, Glesson MAG, Tsai M-J, O'Malley BW. Enhancement of human estrogen receptor activity by SPT6: a potential coactivator. Mol Endocrinol 1995;9:34-43.
24. Yang NN, Venugopalan M, Hardikar S, Glasebrook A. Identification of an estrogen response element activated by metabolites of 17β-estradiol and raloxifene. Science 1996; 273:1222-4.
25. Gradishar WJ, Jordan VC. The clinical potential of new antiestrogens. J Clin Oncol 1997 (in press).
26. Ke HZ, Simmons HA, Pirie CM, Crawford DT, Thompson DD. Droloxifene, a new estrogen antagonist/agonist, prevents bone loss in ovariectomized rats. Endocrinology 1995;136:2435-41.
27. Raushning W, Pritchard KI. Droloxifene, a new antiestrogen: its role in metastatic breast cancer. Breast Cancer Res Treat 1994;31:83-94.
28. White INH, deMatteis F, Davies A, et al. Genotoxic potential of tamoxifen and analogues in female Fischer 344/n rats, DBA/2 and C57BL/6 mice and in human MCL-5 cells. Carcinogenesis 1992;13:2197-203.
29. Hasman M, Rattel B, Loser R, Preclinical data for droloxifene. Cancer Lett 1994;84:101-16.
30. Jordan VC, Phelps E, Lindgren JU. Effect of antiestrogens on bone in castrated and intact female rats. Breast Cancer Res Treat 1987;10:31-5.
31. Gottardis MM, Jordan VC. The antitumor action of keoxifene and tamoxifen in the N-nitrosomethylurea-induced rat mammary carcinoma model. Cancer Res 1987;47:4020-4.
32. Black LJ, Sato M, Rowley ER, et al. (1994) Raloxifene (LY139481 HCl) prevents bone loss and reduces serum cholesterol without causing uterine hypotrophy in ovariectomized rats. J Clin Invest 93:63-9.
33. Evans GL, Bryant HU, Magee D, Sato M, Turner RT. The effects of raloxifene on tibia histomorphometry in ovariectomized rats. Endocrinology 1994;134:2283-8.
34. Sato M. Kim J, Short LL, Szemenda CW, Bryant HU. Longitudinal and cross-sectional analysis of raloxifene effects on tibiae from ovariectomized rats. J Pharmacol Exp Ther 1995;272:1251-9.
35. Black LJ, Jones CD, Falcone JF. Antagonism of estrogen action with a new benzothiophene-derived antiestrogcn. Life Sci 1983;32:1031-6.
36. Biegon A, Brewster M, Degani H, Pop E, Somjen D, Kaye AM. A permanently charged tamoxifen derivative displays anticancer activity and improved tissue selectivity in rodents. Cancer Res 1996;56:4328-31.